
Today, the company said today that it has penetrated the U.S. markets with its BioCalth® product on www.Walmart.com and www.VitaminShoppe.com. This is not the first products helping LTS Nutra to generate revenue in the States as its brands Celadrin® (a cell membrane lubricant) and fit calorie crystals™ are currently sold in national drug store chains and club stores across North America. Additionally, BioCalth is presently being sold in some of the largest drug store chains in Asia and Europe.
“The bone and joint health supplements market continues to rise due to the growing aging population here in the U.S. and we believe BioCalth is unlike any supplement out there in the marketplace today. We are excited that these retailers also sees the potential of BioCalth in the U.S. market and we look forward to what we believe will be a successful brand for many years to come,” stated Chairman of LTS Nutraceuticals, Ted Farnsworth.
Globally, the bone and joint health market expected to top $9 billion in the next five years, with the United States currently representing the largest market in the world.
Shares of LTSN opened are down tepidly by 1.96% at $0.50 on light volume just after the opening bell.
LTS Nutraceuticals (LTSN) Stock Quote and News:
Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.









According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the
0 comments
Add your comment
Commenting is allowed only for registered users.